Related Experiment Video

Updated: Mar 3, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K

CIK Cells and HDAC Inhibitors in Multiple Myeloma

David Stephan1,2, Hans Weiher3, Ingo G H Schmidt-Wolf4

  • 1Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany. david.stephan1701@gmail.com.

International Journal of Molecular Sciences
|May 5, 2017
PubMed

Insights

Combining histone deacetylase (HDAC) inhibitors with cytokine-induced killer cells significantly enhances multiple myeloma treatment efficacy. This novel approach shows superior cancer cell reduction compared to HDAC inhibitors alone, offering a promising therapeutic strategy.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Multiple myeloma, a prevalent hematological malignancy, remains incurable with a median survival of 4-5 years.
  • Current treatments offer limited long-term patient benefit, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of a combined treatment using histone deacetylase (HDAC) inhibitors and cytokine-induced killer (CIK) cells for multiple myeloma.
  • To compare the effectiveness of the combined therapy against HDAC inhibitors as a standalone treatment.

Main Methods:

  • Investigated the impact of HDAC inhibitors alone versus a combination of HDAC inhibitors and CIK cells.
  • Assessed the reduction in cancer cell viability in multiple myeloma cell lines (KMS 18 and U-266).

Main Results:

  • Treatment with HDAC inhibitors alone reduced cell viability to 59% (KMS 18) and 46% (U-266).
  • The combined HDAC inhibitor and CIK cell treatment significantly decreased cell viability to 33% (KMS 18) and 27% (U-266).

Conclusions:

  • The combined therapy demonstrates superior efficacy in reducing multiple myeloma cell viability compared to HDAC inhibitors alone.
  • This combination therapy represents a promising targeted treatment option for multiple myeloma patients.
Keywords:
CIK cellscancer treatmentcytokine-induced killer cellshistone deacetylase inhibitorsimmunotherapymultiple myeloma

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K